Tirzepatide vs Mazdutide: What’s the Difference?
The main difference between Tirzepatide and Mazdutide is mechanism: Tirzepatide is studied for dual-agonist weight loss research — Dual GLP-1 + GIP receptor agonist. Mazdutide is studied for glp-1/glucagon dual agonist weight-loss research — Dual activation of GLP-1 receptors (satiety, insulin) and glucagon receptors (lipolysis, thermogenesis).
GLP-1/GIP dual vs GLP-1/glucagon dual.
Key differences between Tirzepatide and Mazdutide
- •Mechanism: Tirzepatide — Dual GLP-1 + GIP receptor agonist. Mazdutide — Dual activation of GLP-1 receptors (satiety, insulin) and glucagon receptors (lipolysis, thermogenesis).
- •Primary research focus: Tirzepatide is studied for dual-agonist weight loss research; Mazdutide is studied for glp-1/glucagon dual agonist weight-loss research.
- •Overlap: the two compounds share weight loss & metabolism.
- •Discussion context: Tirzepatide is most often discussed alongside dual-agonist weight loss research, while Mazdutide centres on glp-1/glucagon dual agonist weight-loss research.
| Attribute | Tirzepatide Dual GIP/GLP-1 receptor agonist | Mazdutide IBI362, GLP-1/Glucagon dual agonist |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Best known for | Dual-agonist weight loss research | GLP-1/glucagon dual agonist weight-loss research |
| Mechanism of action | Dual GLP-1 + GIP receptor agonist. Stronger appetite suppression and glycemic control than single agonists. | Dual activation of GLP-1 receptors (satiety, insulin) and glucagon receptors (lipolysis, thermogenesis). |
| Human research | Strong | Not catalogued |
| Animal research | Strong | Not catalogued |
| Mechanistic research | Established | Not catalogued |
| Study cadence cited | Once weekly, subcutaneous | — |
| In plain English | Tirzepatide is like Semaglutide with an extra lever pulled. It hits two appetite/insulin pathways at once, producing larger weight reduction in studies. | GLP-1 reduces appetite; glucagon raises energy expenditure. Together they aim for more weight loss than GLP-1 alone. |
| How it works | Co-activates GLP-1 and GIP receptors. GIP enhances insulin response and may help adipose tissue handle nutrients more efficiently while GLP-1 reduces appetite and slows gastric emptying. | Dual activation of GLP-1 receptors (satiety, insulin) and glucagon receptors (lipolysis, thermogenesis). |
| Researchers study | Type 2 diabetes glycemic control, obesity, NASH/MASH, and cardiovascular outcomes. | Obesity and metabolic-associated liver disease, particularly in Chinese clinical research. |
| Internet discussion | Often described as 'Dr. Jay’s Sema on steroids' for weight loss. Heavy discussion of side effect differences and titration schedules. | Discussed alongside survodutide and Retatrutide in next-gen metabolic research. |
Mechanism and research evidence, side by side
How Tirzepatide and Mazdutide differ at the receptor level, and how much published research currently supports each. Evidence ratings describe the depth of publicly available literature — they are not claims of safety or effectiveness.
Tirzepatide
Dual GLP-1 + GIP receptor agonist. Stronger appetite suppression and glycemic control than single agonists.
- Incretin and appetite-regulating receptors
- Slowed gastric emptying and altered satiety signalling
- Energy-balance and glycaemic research endpoints
- Human research
- Strong
- Animal research
- Strong
- Mechanistic research
- Established
Weight loss (typically more aggressive than semaglutide), Type 2 diabetes
Tirzepatide
Dual-agonist weight loss research
Tirzepatide is like Semaglutide with an extra lever pulled. It hits two appetite/insulin pathways at once, producing larger weight reduction in studies.
Co-activates GLP-1 and GIP receptors. GIP enhances insulin response and may help adipose tissue handle nutrients more efficiently while GLP-1 reduces appetite and slows gastric emptying.
Type 2 diabetes glycemic control, obesity, NASH/MASH, and cardiovascular outcomes.
Often described as 'Dr. Jay’s Sema on steroids' for weight loss. Heavy discussion of side effect differences and titration schedules.
Tirzepatide is a dual GLP-1/GIP agonist with strong clinical data for weight reduction and glycemic control.
Mazdutide
GLP-1/glucagon dual agonist weight-loss research
GLP-1 reduces appetite; glucagon raises energy expenditure. Together they aim for more weight loss than GLP-1 alone.
Dual activation of GLP-1 receptors (satiety, insulin) and glucagon receptors (lipolysis, thermogenesis).
Obesity and metabolic-associated liver disease, particularly in Chinese clinical research.
Discussed alongside survodutide and Retatrutide in next-gen metabolic research.
Mazdutide is a GLP-1/glucagon dual agonist researched for obesity and metabolic disease.